211 related articles for article (PubMed ID: 36451864)
1. AKR1C3-dependent lipid droplet formation confers hepatocellular carcinoma cell adaptability to targeted therapy.
Wu C; Dai C; Li X; Sun M; Chu H; Xuan Q; Yin Y; Fang C; Yang F; Jiang Z; Lv Q; He K; Qu Y; Zhao B; Cai K; Zhang S; Sun R; Xu G; Zhang L; Sun S; Liu Y
Theranostics; 2022; 12(18):7681-7698. PubMed ID: 36451864
[No Abstract] [Full Text] [Related]
2. Aldo-keto reductase family member C3 (AKR1C3) promotes hepatocellular carcinoma cell growth by producing prostaglandin F2α.
Jeng KS; Cheng PY; Lin YH; Liu PC; Tseng PH; Wang YC; Chang CF; Leu CM
Oncol Res; 2023; 32(1):163-174. PubMed ID: 38188684
[TBL] [Abstract][Full Text] [Related]
3. Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Abbattista MR; Jamieson SM; Gu Y; Nickel JE; Pullen SM; Patterson AV; Wilson WR; Guise CP
Cancer Biol Ther; 2015; 16(4):610-22. PubMed ID: 25869917
[TBL] [Abstract][Full Text] [Related]
4. Loss of lncRNA LINC01056 leads to sorafenib resistance in HCC.
Chan YT; Wu J; Lu Y; Li Q; Feng Z; Xu L; Yuan H; Xing T; Zhang C; Tan HY; Feng Y; Wang N
Mol Cancer; 2024 Apr; 23(1):74. PubMed ID: 38582885
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of AKR1C3 Promoted Sorafenib Sensitivity Through Inhibiting the Phosphorylation of AKT in Hepatocellular Carcinoma.
Zheng J; Yang Z; Li Y; Yang L; Yao R
Front Oncol; 2022; 12():823491. PubMed ID: 35359392
[TBL] [Abstract][Full Text] [Related]
6. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma.
Bergamini C; Leoni I; Rizzardi N; Melli M; Galvani G; Coada CA; Giovannini C; Monti E; Liparulo I; Valenti F; Ferracin M; Ravaioli M; Cescon M; Vasuri F; Piscaglia F; Negrini M; Stefanelli C; Fato R; Gramantieri L; Fornari F
J Exp Clin Cancer Res; 2023 Jun; 42(1):145. PubMed ID: 37301960
[TBL] [Abstract][Full Text] [Related]
7. AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway.
Chen J; Zhang J; Tian W; Ge C; Su Y; Li J; Tian H
Mol Carcinog; 2023 Jun; 62(6):833-844. PubMed ID: 36920042
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells.
Yang PM; Lin LS; Liu TP
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31936661
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic and prognostic values of AKR1C3 and AKR1D1 in hepatocellular carcinoma.
Zhu P; Feng R; Lu X; Liao Y; Du Z; Zhai W; Chen K
Aging (Albany NY); 2021 Jan; 13(3):4138-4156. PubMed ID: 33493134
[TBL] [Abstract][Full Text] [Related]
10. Macropinocytosis is an alternative pathway of cysteine acquisition and mitigates sorafenib-induced ferroptosis in hepatocellular carcinoma.
Byun JK; Lee S; Kang GW; Lee YR; Park SY; Song IS; Yun JW; Lee J; Choi YK; Park KG
J Exp Clin Cancer Res; 2022 Mar; 41(1):98. PubMed ID: 35287706
[TBL] [Abstract][Full Text] [Related]
11. Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib.
Bai J; Liu Z; Liu J; Zhang S; Tian Y; Zhang Y; Ren L; Kong D
Aging (Albany NY); 2019 Dec; 11(24):12452-12475. PubMed ID: 31881007
[TBL] [Abstract][Full Text] [Related]
12. Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.
Jo H; Park Y; Kim T; Kim J; Lee JS; Kim SY; Chung JI; Ko HY; Pyun JC; Kim KS; Lee M; Yun M
BMC Cancer; 2020 Apr; 20(1):332. PubMed ID: 32306906
[TBL] [Abstract][Full Text] [Related]
13. AKR1C3 silencing inhibits autophagy-dependent glycolysis in thyroid cancer cells by inactivating ERK signaling.
Gao Y; Tao W; Wang S; Duan R; Zhang Z
Drug Dev Res; 2024 Feb; 85(1):e22142. PubMed ID: 38349266
[TBL] [Abstract][Full Text] [Related]
14. Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma.
Lai YL; Wang KH; Hsieh HP; Yen WC
J Biomed Sci; 2022 Jan; 29(1):5. PubMed ID: 35062934
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
Turcios L; Vilchez V; Acosta LF; Poyil P; Butterfield DA; Mitov M; Marti F; Gedaly R
Dig Liver Dis; 2017 Jun; 49(6):697-704. PubMed ID: 28179093
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of glycogen catabolism induces intrinsic apoptosis and augments multikinase inhibitors in hepatocellular carcinoma cells.
Barot S; Abo-Ali EM; Zhou DL; Palaguachi C; Dukhande VV
Exp Cell Res; 2019 Aug; 381(2):288-300. PubMed ID: 31128107
[TBL] [Abstract][Full Text] [Related]
17. AKR1C3 regulated by NRF2/MAFG complex promotes proliferation via stabilizing PARP1 in hepatocellular carcinoma.
Pan D; Yang W; Zeng Y; Qin H; Xu Y; Gui Y; Fan X; Tian G; Wu Y; Sun H; Ye Y; Yang S; Zhou J; Guo Q; Zhao L
Oncogene; 2022 Jul; 41(31):3846-3858. PubMed ID: 35773412
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol sensor SCAP contributes to sorafenib resistance by regulating autophagy in hepatocellular carcinoma.
Li D; Yao Y; Rao Y; Huang X; Wei L; You Z; Zheng G; Hou X; Su Y; Varghese Z; Moorhead JF; Chen Y; Ruan XZ
J Exp Clin Cancer Res; 2022 Mar; 41(1):116. PubMed ID: 35354475
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia induces sorafenib resistance mediated by autophagy via activating FOXO3a in hepatocellular carcinoma.
Liang C; Dong Z; Cai X; Shen J; Xu Y; Zhang M; Li H; Yu W; Chen W
Cell Death Dis; 2020 Nov; 11(11):1017. PubMed ID: 33250518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
